Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 0.96

Daewoong pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) is 0.96 on January 14, 2025, a 4.56% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Daewoong pharmaceutical Co.,Ltd 52-week high Price to Sales Ratio (P/S) is 1.30 on October 11, 2024, which is 35.56% above the current Price to Sales Ratio (P/S).
Daewoong pharmaceutical Co.,Ltd 52-week low Price to Sales Ratio (P/S) is 0.78 on June 26, 2024, which is -17.99% below the current Price to Sales Ratio (P/S).
Daewoong pharmaceutical Co.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 0.98.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years